Healthcare | May 29, 2025
USV’s ‘United for BP Control’ Mission takes aim at India’s blood pressure epidemic
The initiative was announced at World Hypertension Congress, Chennai
The initiative was announced at World Hypertension Congress, Chennai
Usnoflast has previously also received ‘Orphan Drug Designation (ODD)’ from the USFDA
The company reported sustained increase in formulations' share despite slowdown in productivity of Gagillapur facility
Adjusted EBITDA positive at Rs. 3.1 crore despite investments in marketing, talent hiring and technology over the year
Facility also named 2025 ISPE Facility of the Year Winner for Social Impact - Unmet Medical Needs
The company recorded its quarterly consolidated revenue from operations at Rs. 61.22 crore in Q4 FY25
The revenue witnessed a growth of 7.80 per cent on a year-on-year basis at Rs. 2,959 crore
The company expects meaningful revenue contribution from this long-term agreement
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
Subscribe To Our Newsletter & Stay Updated
